Digital Health Global
SEPTEMBER 27, 2023
With these resources, Automera is well positioned to deploy our AUTAC platform toward the development of potentially transformative therapies.” About Automera Automera is an early-stage company focused on the development of a novel therapeutic approach via autophagy-based targeted protein degradation.
Healthcare IT Today
OCTOBER 6, 2023
The funding enables Atropos Health to accelerate commercial and development opportunities outside the U.S., This platform is designed to meet the demands of health systems and life science companies working to solve increasingly global, diverse, and data-intensive healthcare problems.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Digital Health Global
JUNE 20, 2023
Founded in 2018 and supported from the outset by LallianSe, the life sciences integrator, BrainTale has developed and commercializes an accessible, reliable and clinically validated brain measurement digital platform solution for drug developers and physicians – neurologists, neuroradiologists and intensivists.
Digital Health Global
JANUARY 8, 2024
AI-powered* platform takes eCOA off the critical path to study startup for life sciences industry PALO ALTO, Calif.–(BUSINESS –(BUSINESS WIRE)– Medable Inc. , Medable, which ranked in the top 8% of software companies on the 2023 Inc.
Healthcare IT Today
JANUARY 8, 2024
We asked the Healthcare IT Today community to submit their predictions and we received a wide ranging set of responses that we grouped into a number of themes. Jane Reed, Director of Life Sciences at Linguamatics, an IQVIA company Pharmaceutical developers have always prioritized drug safety.
Healthcare IT Today
MAY 22, 2023
“We are excited to have the support of such a strong group of investors who share our mission of unlocking the power of data to improve health,” said Sundeep Bhan, CEO at Prognos Health.
Digital Health Global
FEBRUARY 16, 2023
“Avilar is pioneering the next frontier in protein degradation and we are excited that our significant progress over the past year in discovering and advancing extracellular protein degraders has attracted this group of leading investors,” said Daniel Grau, CEO and President of Avilar Therapeutics. Find out more: www.sanofiventures.com.
Expert insights. Personalized for you.
88 
Let's personalize your content